Share ownership Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-02-06 am EST			5-day change	1st Jan Change
80.36 ^EUR	-0.90%		+4.26%	-2.85%

Feb. 06	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
Feb. 05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI

Share class: Sanofi

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,263,122,721	1,102,839,922 ( 87.31 %)	15,330,000 ( 1.214 %)	87.31 %

Major shareholders: Sanofi

Name	Equities	%	Valuation
L'ORÉAL 7.271 %	88,670,657	7.271 %	8 614 M €
SANOFI 0.7816 %	9,531,081	0.7816 %	926 M €
OFI Invest Asset Management SA 0.3009 %	3,670,055	0.3009 %	357 M €
Goldman Sachs Asset Management BV 0.1647 %	2,008,712	0.1647 %	195 M €
State Street Global Advisors Ltd. 0.1373 %	1,674,950	0.1373 %	163 M €
Sjunde AP-fonden 0.1276 %	1,556,065	0.1276 %	151 M €
Financière de l'Échiquier SA 0.0914 %	1,115,098	0.0914 %	108 M €
Capfi Delen Asset Management NV 0.0892 %	1,088,070	0.0892 %	106 M €
Sparinvest SA (Denmark) 0.0792 %	965,274	0.0792 %	94 M €
Storebrand Asset Management AS 0.0637 %	777,033	0.0637 %	75 M €
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Dodge & Cox 2.826 %	68,931,747	2.826 %	3 340 M €
Fisher Asset Management LLC 0.5157 %	12,578,746	0.5157 %	610 M €
Merrill Lynch International 0.4048 %	9,872,475	0.4048 %	478 M €
Eaton Vance Management 0.31 %	7,561,925	0.31 %	366 M €
Barrow, Hanley, Mewhinney & Strauss LLC 0.2922 %	7,126,993	0.2922 %	345 M €
T. Rowe Price International Ltd. 0.2408 %	5,873,539	0.2408 %	285 M €
Invesco Advisers, Inc. 0.2377 %	5,797,547	0.2377 %	281 M €
Wells Fargo Bank NA 0.1852 %	4,516,037	0.1852 %	219 M €
Wellington Management International Ltd. 0.1691 %	4,123,755	0.1691 %	200 M €
Fiduciary Trust Company International 0.1612 %	3,931,758	0.1612 %	191 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	20.73%
L'Oréal SA	7.27%
Other	1.48%
Sanofi	0.78%
Regal Partners Ltd.	0.14%
SEI Investments Co.	0.06%
Manulife Financial Corp.	0.01%
Zions Bancorporation NA	0.01%
Northwest Bancshares, Inc. (Pennsylvania)	0.01%
Unknown	69.51%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	16.34%
France	8.83%
United Kingdom	2.46%
Canada	0.5%
Ireland	0.21%
Netherlands	0.21%
Germany	0.2%
Belgium	0.19%
Sweden	0.19%
Spain	0.17%
Italy	0.17%
Norway	0.16%
Switzerland	0.16%
Australia	0.15%
Luxembourg	0.13%
Denmark	0.12%
Finland	0.1%
Austria	0.05%
New Zealand	0.03%
South Africa	0.02%
Israel	0.02%
Japan	0.02%
Liechtenstein	0.01%
China	0.01%
Hong Kong	0.01%
Mexico	0.01%
Cyprus	0.01%
Individuals	-.--%

Based on 1000 largest holdings

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2024, the group had 52 production sites worldwide. In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation. Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Employees

82,878

Sector

Pharmaceuticals

Calendar

Apr. 22 - Q1 2026 Earnings Call

More about the company